UNSPSC 51182417: Risedronate sodium or risedronic acid

This classification denotes a bone resorption inhibitor and biphosphonate with the molecular formula C7H11NO7P2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KM2Z91756Z, chemically known as phosphonic acid, (1-hydroxy-2-(3-pyridinyl)ethylidene)bis- but generally known as risedronic acid, which bears US NIH Compound Identifier 5245. European Medicines Agency schedules Risedronic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10330MIG.

The term RISEDRONIC ACID is an International Non-Proprietary Name. World Health Organization schedules risedronic acid in its Anatomical Therapeutic Chemical (ATC) Classification. Risedronate sodium or risedronic acid bears US NLM identifiers UMLS ID C0140610 and NCI Concept Code C66517. SMILES: P(=O)(O)(O)C(P(=O)(O)O)(O)CC1CCCNC1.

UNSPSC 51182417 Risedronate sodium or risedronic acid is a Commodity code that nominally addresses a specific pharmaceutical product, but the recent state and local opportunities posted under this code show little direct relevance to risedronate procurement. Instead, the opportunities span athletic training services, general medical aid supplies, water treatment chemicals, and pharmacy benefit program inquiry — none of which align with the code's stated pharmaceutical scope. The City of Tucson is seeking comprehensive athletic training services for fire and police departments through an RFP due June 9, 2026, with injury prevention, rehabilitation, and return-to-duty support as core deliverables; the City of Tampa's Fire Rescue Department posted an ITB for a broad range of first aid and medical supplies with an estimated annual budget of $100,000; and the County of Orange is bidding sodium hypochlorite and sulfuric acid for water treatment operations. The Texas Health and Human Services Commission issued an RFI on direct-to-manufacturer prescription fulfillment capability, which touches on pharmaceutical channels but not risedronate specifically. This mismatch suggests that the code classification does not reflect the actual procurement activity being tagged under it at the state and local level.

The geographic spread of recent opportunities includes Arizona (Tucson), Florida (Tampa), California (Orange County), and Texas (HHS), but the diversity of commodity types and the absence of any risedronate-specific solicitations indicates minimal meaningful market signal under this code. State and local buyers appear to be using this code for broader health, safety, and pharmaceutical-adjacent services rather than for the specific osteoporosis medication the code nominally describes. A firm pursuing this code should verify whether opportunities are actually risedronate-related before committing bid resources, as current activity shows little alignment with the pharmaceutical product name.